Lupeng Pharmaceutical Enrolls First Patient in ROCKET-CLL Trial for Novel BTK Inhibitor Rocbrutinib

An Important Milestone in Leukemia Treatment

Lupeng Pharmaceutical Ltd, a leading biopharmaceutical company, has launched a significant global clinical trial aimed at revolutionizing treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The company recently announced that the first patient has been enrolled in its Phase 3 ROCKET-CLL trial, a head-to-head comparison of its investigational drug, rocbrutinib (LP-168), against another treatment, pirtobrutinib.

Background of the Study

The ROCKET-CLL trial is particularly important in light of the challenges faced by existing Bruton's tyrosine kinase (BTK) inhibitors, which can become ineffective due to resistance mutations. Rocbrutinib is notable for being the first fourth-generation BTK inhibitor designed specifically to address these challenges. This study is comprehensive, involving multiple sites globally and aiming to enroll approximately 306 participants.

The first enrollment took place at the OptumCare Cancer Care Center in Las Vegas, under the expert direction of Dr. Russell Gollard. The trial aims to assess the efficacy and safety of rocbrutinib in patients who have previously undergone therapy with a covalent BTK inhibitor, addressing a critical need for effective treatments in relapsed and refractory cases of CLL/SLL.

Structure and Goals of the ROCKET-CLL Trial

The trial is structured as a randomized, open-label study, where participants will receive once-daily doses of either rocbrutinib or pirtobrutinib, both dosed at 200 mg. The main goal is to measure progression-free survival (PFS), while secondary objectives include assessing overall survival (OS), overall response rate (ORR), and duration of response (DOR). Additionally, the trial will explore the safety and tolerability of each treatment.

With a robust design, the trial is expected to yield significant insights into treatment responses and the mechanisms behind resistance in CLL/SLL patients. Enrollment is projected to conclude by the fourth quarter of 2027, followed by interim data analysis in 2029.

The Mechanism of Rocbrutinib (LP-168)

Rocbrutinib, developed via Lupeng's proprietary BeyondX platform, is described as a differentiated BTK inhibitor that combines both covalent and non-covalent mechanisms. This innovative approach allows it to inhibit various forms of BTK, including mutated variants, enhancing its potential efficacy against multiple types of resistance. Clinical trials indicate that rocbrutinib has a strong safety profile, with promising response rates observed in earlier studies.

Rocbrutinib's New Drug Application (NDA) for treated relapsed or refractory mantle cell lymphoma in China is currently under review, and it has also received Breakthrough Therapy Designation for certain aggressive lymphoma cases.

Lupeng's Commitment to Innovation

Lupeng Pharmaceutical is dedicated to developing advanced therapies for hematological malignancies, leveraging its innovative medicinal chemistry platforms to address critical medical needs. The company’s swift progression underscores its commitment to efficacy in cancer treatment, and the ROCKET-CLL trial may mark a pivotal turn in the management of CLL/SLL moving forward.

As the clinical trial unfolds, many within the medical community are eagerly awaiting results, hopeful that rocbrutinib will emerge as a key player in the ongoing fight against hemolytic cancers.

For more information about the trial and Lupeng's ongoing research efforts, please visit www.lupengbio.com.